ARTICLE | Clinical News

Rilutek data

May 15, 1995 7:00 AM UTC

RPR presented more detail of previously announced results of its Phase III trial at the meeting of the American Academy of Neurology in Seattle, showing an effect on survival.

The number of patients still alive after 18 months increased by 12.7 percent in patients receiving a 100 mg daily dose of drug compared to placebo (p=0.076 and 0.05 by two different statistical tests). ...